Nakayama Harumi, Toho Hiroyuki, Sone Teruki
Medical Corporation Mishokai Harumi Clinic, Yashio, Japan.
Hitachi, Ltd., Tokyo, Japan.
Osteoporos Sarcopenia. 2018 Mar;4(1):29-32. doi: 10.1016/j.afos.2018.02.001. Epub 2018 Mar 5.
As clinics that treat patients with osteoporosis do not usually have central dual-energy X-ray absorptiometry (DXA), bone density is often measured with radial DXA. However, no long-term evidence exists for radius bone density outcomes following treatment with once-weekly teriparatide in actual medical treatment.
We evaluated changes in bone density at 6-, 12-, and 18-month intervals using radial DXA in patients treated with once-weekly teriparatide for more than 6 months.
A significant increase in bone mineral density (BMD) was observed at the 1/3 and 1/10 radius sites 12 months after the initiation of once-weekly teriparatide. We also observed that the rate of change in BMD was greater at the distal 1/10 radius than at the 1/3 radius.
Considering these points, the effect of once-weekly teriparatide therapy can be observed at the radius. In clinics that do not have central DXA, but instead have radial DXA, these findings can help to evaluate the effect of once-weekly teriparatide treatment on osteoporosis.
由于治疗骨质疏松症患者的诊所通常没有中央双能X线吸收测定法（DXA），骨密度常采用桡骨DXA进行测量。然而，在实际医疗中，对于每周一次使用特立帕肽治疗后的桡骨骨密度结果，尚无长期证据。
我们对接受每周一次特立帕肽治疗超过6个月的患者，使用桡骨DXA评估其在6个月、12个月和18个月时骨密度的变化。
在开始每周一次使用特立帕肽12个月后，桡骨1/3和1/10部位的骨矿物质密度（BMD）显著增加。我们还观察到，桡骨远端1/10处的BMD变化率大于桡骨1/3处。
考虑到这些情况，每周一次使用特立帕肽治疗的效果在桡骨处可以观察到。在没有中央DXA但有桡骨DXA的诊所中，这些发现有助于评估每周一次使用特立帕肽治疗骨质疏松症的效果。
